US 2014/0194466 A1 · PERHEXILINE FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY (HCM)

Abstract

The invention relates to perhexiline, or a pharmaceutically acceptable salt or enantiomer thereof, for use in the treatment of hypertrophic cardiomyopathy, as well as to a method of treating HCM, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt or enantiomer thereof, to treat said HCM. The invention further relates to a treatment programme for treating HCM, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HCM or the symptoms thereof.

Claims20

Dependent claims

A method for treating hypertrophic cardiomyopathy in a mammal in need thereof, comprising:

diagnosing the mammal as having hypertrophic cardiomyopathy or at least one of a symptomatic component, feature or condition thereof;
and
administering to said mammal a therapeutically-effective amount of (−)-perhexiline.

Dependencies are inferred from the claim text.

Facts

Application

14/186,554Filed 21 Feb 2014

Priority

GB 0908193.613 May 2009

Published

10 Jul 2014

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 31/4458
Non condensed piperidines, e.g. piperocaine: only substituted in position 2, e.g. methylphenidate
A61K 31/366
Lactones: having six-membered rings, e.g. delta-lactones
A61K 31/445
Non condensed pyridines; Hydrogenated derivatives thereof: non condensed piperidines, e.g. piperocaine
A61P 9/00
Drugs for disorders of the cardiovascular system

Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm)

Life of this patent

Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm)

Life of this patent

Abstract

Claims20